Hims and Hers misses quarterly profit estimates-March 2024-www.financetom.com

Hims and Hers misses quarterly profit estimates

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Hims and Hers misses quarterly profit estimates

Nov 3, 2025 1:27 PM

Nov 3 (Reuters) - Hims and Hers Health ( HIMS ) missed

Wall Street estimates for third-quarter profit on Monday, hit by

increased product costs and reduced unit sales in the telehealth

company's weight-loss business.

The company reported an adjusted profit of 6 cents per share

for the quarter ended September 30, lower than the average

analyst estimate of 10 cents per share, according to LSEG data.

Previous page： Hyperscale Data Unveils Bold Bitcoin Treasury Plan Next page： Lifezone Metals Closes $60 Million Bridge Loan From Taurus Mining

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Hyperscale Data Unveils Bold Bitcoin Treasury Plan

Sep 2, 2025

Hyperscale Data, Inc. ( GPUS/PD ) saw its shares slip in Tuesday's premarket trading after unveiling plans to purchase roughly $20 million worth of Bitcoin (CRYPTO: BTC/USD) for its treasury. The move will be financed in part through proceeds from its recently announced at-the-market equity offering. The company, currently valued at around $15 million, said it views its true asset...

Lifezone Metals Closes $60 Million Bridge Loan From Taurus Mining

Sep 2, 2025

08:03 AM EDT, 09/02/2025 (MT Newswires) -- Lifezone Metals ( LZM ) said Tuesday its wholly-owned subsidiary, Kabanga Nickel has closed the $60 million bridge loan facility agreement with Taurus Mining Finance Fund. The company further added that it has received the first tranche of $20 million under the bridge loan from Taurus and the future tranches may be disbursed...

Stoke Therapeutics, Biogen Say Studies Support Potential of Dravet Syndrome Treatment

Sep 2, 2025

08:00 AM EDT, 09/02/2025 (MT Newswires) -- Stoke Therapeutics ( STOK ) and Biogen (BIIB) said Tuesday that data from the phase 1/2a and open-label extension studies of zorevunersen supported the potential of the investigational drug to treat Dravet syndrome. Across the studies, the drug showed substantial and durable reductions in major motor seizure frequency and continuing improvements in cognition,...

Market Chatter: Amazon US Prime Sign-Ups Fall Short of Last Year Tally, Company Target

Sep 2, 2025

08:00 AM EDT, 09/02/2025 (MT Newswires) -- Amazon.com's ( AMZN ) US Prime sign-ups fell short of last year's aggregate and the company's own targets, Reuters reported Tuesday, citing internal data. The e-commerce giant registered 5.4 million US sign-ups over the 21-day run-up to Prime Day and its four-day sales event from July 8 through July 11, according to the...